Assessing comparative effectiveness of new drugs before approval using prospective network meta-analyses.

Abstract

Comparative efficacy and safety data are often lacking at the time of new drug approval for market entry. Regulatory agencies in the United States (the Food and Drug Administration [FDA]) and the European Union (the European Medicines Agency [EMA]) often evaluate each new drug on its own (often in placebo-controlled trials), and without comparative… (More)
DOI: 10.1016/j.jclinepi.2013.04.002

1 Figure or Table

Topics

  • Presentations referencing similar topics